Semaglutide for Methamphetamine Addiction

(GEM Trial)

This trial explores a medication called semaglutide (Wegovy) to assist individuals struggling with methamphetamine addiction. Researchers aim to determine if this medication can reduce meth use and assess its safety and acceptance among participants. The trial consists of two parts: an initial study with 25 participants all taking semaglutide, followed by a larger study where participants are randomly assigned to either semaglutide or a placebo (a pill with no active drug). Suitable candidates have used meth frequently in the past month and wish to quit or reduce their use. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group.

You may need to stop taking certain medications before joining the trial. Specifically, if you've used medications for weight management or certain diabetes medications in the past 30 days, you might not be eligible. It's best to discuss your current medications with the study team to see if they affect your eligibility.

Research has shown that semaglutide, the treatment being tested for methamphetamine addiction, has been studied for its safety and potential benefits. Some studies suggest it might help reduce hospital visits related to substance use and lower the risk of overdose. Semaglutide, a GLP-1 receptor agonist, has been linked to a 14% lower risk of developing any substance use disorder.

Unlike the standard treatments for methamphetamine addiction, which typically involve behavioral therapies and supportive medications like antidepressants, semaglutide is unique because it is traditionally used for managing type 2 diabetes and obesity. This drug works by mimicking a hormone called GLP-1 that regulates appetite and insulin levels, which might help reduce cravings and addictive behaviors associated with methamphetamine use. Researchers are excited about semaglutide because it offers a novel approach by potentially addressing the biological aspects of addiction, which current therapies do not directly target.

Research has shown that semaglutide, also known as Wegovy, might help treat methamphetamine use disorder (MeUD). In this trial, participants will receive either semaglutide or a placebo. Studies have found that medications like semaglutide can lower substance use and its harmful effects. Specifically, semaglutide has been linked to a reduced risk of developing substance use disorders. Additionally, similar drugs have shown potential in reducing methamphetamine use. These findings suggest that semaglutide could help decrease methamphetamine addiction by influencing brain pathways involved in addiction.¹²³⁴⁵